South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S
You may also be interested in...
Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses
The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.
Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses
The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.
South Korea Starts Onsite Inspections Of Essential Drug Reserves Amid Tension With North Korea
As tensions between South and North Korea simmer, South Korea is conducting its first on-site inspections of drug reserves since 2006.